Sal Guccione

Mr. Guccione has been associated with Behrman Capital since 2006. His career includes over thirty years of CEO, CFO and strategy/M&A experience in pharmaceutical outsourcing, with particular focus in the CDMO and CRO sectors of pharmaceutical research, development and manufacture. Mr. Guccione was the CEO of Behrman portfolio company WIL Research, a leading international nonclinical pharmaceutical contract research organization, which today is part of Charles River Laboratories. Most recently, Mr. Guccione was the Executive Chairman of Emmes Corporation, a clinical stage CRO owned by Behrman. Earlier in his career, from 1987 to 2005, he held a series of senior management positions in strategy, M&A, finance and general management at Cambrex Corporation, a leading, global CDMO for active pharmaceutical ingredients, and at International Specialty Products, a leading manufacturer and marketer of specialty chemicals to the pharmaceutical, personal care and industrial markets.